COMPARE头对头随机对照试验:SEL-212(pegadricase联合含雷帕霉素纳米颗粒ImmTOR™)对比pegloticase治疗难治性痛风
COMPARE是一项随机、2期、开放标签试验,在难治性痛风成人中比较SEL-212(每月输注ImmTOR 0.15 mg/kg与pegadricase 0.2 mg/kg)与pegloticase(8 mg,每两周一次)治疗6个月。第3和第6个月合计,SEL-212组53.0% vs pegloticase组46.0%的参与者达到并维持血尿酸<6 mg/dl且时间≥80%(P=0.181)。SEL-212组血尿酸降幅更大(-73.79% vs -47.96%,P=0.0161),痛风发作和关节计数减少相当,SEL-212输注频率更低。
要点
- SEL-212组53.0% vs pegloticase组46.0%达到血尿酸<6 mg/dl且时间≥80%(P=0.181)。
- SEL-212组血尿酸降幅-73.79% vs pegloticase组-47.96%(P=0.0161)。
- SEL-212组口腔炎8例(9.6%) vs pegloticase组0例,与ImmTOR相关。
核心结论
- SEL-212在难治性痛风中的疗效和耐受性与pegloticase相当,且因输注频率降低而大幅减少治疗负担。
研究设计与样本
- COMPARE为随机、2期、开放标签试验,在难治性痛风成人中比较SEL-212与pegloticase。
- SEL-212组每月输注ImmTOR(0.15 mg/kg)和pegadricase(0.2 mg/kg),pegloticase组每两周输注pegloticase(8 mg),疗程6个月。
主要发现
- 第3和第6个月合计,SEL-212组53.0% vs pegloticase组46.0%的参与者达到并维持血尿酸<6 mg/dl且时间≥80%(P=0.181)。
- 第3和第6个月,SEL-212组血尿酸降幅-73.79% vs pegloticase组-47.96%(P=0.0161)。
- 痛风发作发生率和压痛和/或肿胀关节数在两组间相当。
- SEL-212组 vs pegloticase组最常见治疗相关不良事件:痛风发作60.2% vs 50.6%,感染25.3% vs 18.4%,输注相关反应15.7% vs 11.5%。
- SEL-212组8例参与者(9.6%)出现口腔炎(及相关术语),pegloticase组0例;口腔炎为雷帕霉素已知事件,仅与ImmTOR相关。
关键数值与推荐
- 主要终点:第3和第6个月期间血尿酸<6 mg/dl且时间≥80%的参与者比例,SEL-212组53.0% vs pegloticase组46.0%(P=0.181)。
- 血尿酸降幅:SEL-212组-73.79% vs pegloticase组-47.96%(P=0.0161)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Serum urate (SU) lowering with PEGylated uricases in gout can reduce flares and tophi. However, treatment-emergent anti-drug antibodies adversely affect safety and efficacy and the currently approved PEGylated uricase pegloticase requires twice-monthly infusions. Investigational SEL-212 therapy aims to promote uricase-specific tolerance via monthly sequential infusions of a proprietary rapamycin-containing nanoparticle (ImmTOR) and pegadricase. METHODS: COMPARE was a randomized, phase 2, open-label trial of SEL-212 vs pegloticase in adults with refractory gout. SEL-212 [ImmTOR (0.15 mg/kg) and pegadricase (0.2 mg/kg)] was infused monthly or pegloticase (8 mg) twice monthly for 6 months. The primary endpoint was the proportion of participants with SU <6 mg/dl for ≥80% of the time during 3 and 6 months. Secondary outcomes were mean SU, gout flares, number of tender and/or swollen joints and safety. RESULTS: During months 3 and 6 combined, numerically more participants achieved and maintained a SU <6 mg/dl for ≥80% of the time with SEL-212 vs pegloticase (53.0% vs 46.0%, P = 0.181). The percentage reductions in SU levels were statistically greater during months 3 and 6 with SEL-212 vs pegloticase (-73.79% and -47.96%, P = 0.0161). Reductions in gout flare incidence and number of tender and/or swollen joints were comparable between treatments. There were numerical differences between the most common treatment-related adverse events of interest with SEL-212 and pegloticase: gout flares (60.2% vs 50.6%), infections (25.3% vs 18.4%) and infusion-related reactions (15.7% vs 11.5%), respectively. Stomatitis (and related terms) was experienced by eight participants (9.6%) with SEL-212 and none with pegloticase. Stomatitis, a known event for rapamycin, was associated with ImmTOR only. CONCLUSIONS: SEL-212 efficacy and tolerability were comparable to pegloticase in refractory gout. This was associated with a substantial reduction in treatment burden with SEL-212 due to decreased infusion frequency vs pegloticase. CLINICAL TRIAL REGISTRATION: NCT03905512.
引用
- Baraf HSB, Khanna PP, Kivitz AJ, et al. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout. Rheumatology (Oxford). 2024. PMID: 37449908. doi:10.1093/rheumatology/kead333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。